Triglav Investments D.O.O. Cuts Stock Holdings in Astrazeneca Plc $AZN

Triglav Investments D.O.O. reduced its position in Astrazeneca Plc (NYSE:AZN) by 63.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,618 shares of the company’s stock after selling 63,617 shares during the quarter. Triglav Investments D.O.O.’s holdings in Astrazeneca were worth $7,217,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Triumph Capital Management purchased a new stake in Astrazeneca during the third quarter valued at about $25,000. MV Capital Management Inc. acquired a new position in shares of Astrazeneca in the 4th quarter valued at about $26,000. Mascoma Wealth Management LLC purchased a new stake in shares of Astrazeneca during the 1st quarter worth about $26,000. Bangor Savings Bank grew its holdings in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Finally, Eagle Bay Advisors LLC acquired a new stake in Astrazeneca during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Stock Up 0.1%

Shares of Astrazeneca stock opened at $171.86 on Monday. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a market capitalization of $266.54 billion, a PE ratio of 25.80, a P/E/G ratio of 1.39 and a beta of 0.24. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The business has a 50-day moving average of $183.68 and a 200-day moving average of $188.73.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, equities analysts forecast that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Negative Sentiment: Wainua’s Phase 3 failure removes a potential growth driver and raises concerns about AstraZeneca’s ability to expand successfully beyond oncology. Reuters: AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
• Negative Sentiment: Several reports say the miss has hurt management credibility and triggered a sharp market selloff, with investors reassessing the value of AstraZeneca’s pipeline. Proactive Investors: AstraZeneca’s Wainua failure hurts credibility more than valuation, Jefferies warns
• Neutral Sentiment: Some analysts still maintained a constructive view, with Bernstein reportedly reiterating a buy rating despite the setback, suggesting the longer-term thesis is not fully broken. Globe and Mail/Bernstein note: AstraZeneca receives a Buy from Bernstein
• Negative Sentiment: Investor concern has also expanded into legal overhangs, with a pending investigation notice adding another source of pressure on the stock. PR Newswire: AstraZeneca Investigation Notice

Wall Street Analyst Weigh In

AZN has been the topic of several research reports. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Finally, UBS Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.